News | August 13, 2008

Study Says Usage of Ultrasound Contrast Agents in Echocardiography Declined

August 14, 2008 - Arlington Medical Resources (AMR), a provider of market intelligence for the pharmaceutical and diagnostic imaging industries, found the usage of injectable perflutren microsphere ultrasound (micro-bubble) contrast agents, which help to evaluate heart wall motion, declined in the second quarter of 2008 to 22 percent of the usage just two years earlier.

Micro-bubble contrast agents are gas-filled microspheres injected intravenously to improve cardiac ultrasound scanning. In October 2007 the FDA placed a black box warning on ultrasound micro-bubble contrast agents after 10 deaths were reported following administration. Reports of 190 serious but nonfatal reactions were also documented.

“The effects of the black box warnings in 2007 are still being felt in the micro-bubble contrast agent market,” said Anna Fisher, an analyst at AMR. “Even after the FDA revised its warning in May 2008 allowing the agents to be used more broadly, usage still declined in the second quarter of 2008. The role of ultrasound contrast agents continues to be important in the overall echocardiography market because it enhances imaging quality for interpretation. Contrast improves visualization of the left ventricle border, helping the physician evaluate wall motion of the heart.”

The newly released edition of the U.S. Echocardiography Monthly Monitor also finds that the total number of patients undergoing echocardiographies in the U.S. had declined by 17,095 in June 2008. The total number of patients undergoing contrast enhanced echocardiography for the U.S. market also declined slightly by 2,137.

For more information: www.AMR-data.com

Related Content

FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media| September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media| August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media| July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media| July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media| June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media| March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media| February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians

News | Contrast Media| January 30, 2017
Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be...
GE Healthcare, Optison ultrasound contrast agent, FDA labeling change, cardiac shunts, intra-arterial injection
Technology | Contrast Media| October 04, 2016
GE Healthcare announced that the U.S. Food and Drug Administration (FDA) has approved a label change for the ultrasound...
MR angiography, MRA, Bayer, Gadavist, gadobutrol injection, FDA approval, supra-aortic arteries
Technology | Contrast Media| April 29, 2016
Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Gadavist (gadobutrol) injection for use...
Overlay Init